Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation

被引:67
作者
Khan, IA
Mehta, NJ
Gowda, RM
机构
[1] Creighton Univ, Sch Med, Dept Med, Div Cardiol, Omaha, NE 68131 USA
[2] Long Isl Coll Hosp, Dept Med, Div Cardiol, Brooklyn, NY 11201 USA
关键词
atrial fibrillation; amiodarone; pharmacological cardioversion; chemical cardioversion; class III antiarrhythmic drugs;
D O I
10.1016/S0167-5273(02)00477-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy and safety of amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search. Amiodarone has been used both intravenously (i.v.) and orally for the pharmacological cardioversion of recent-onset atrial fibrillation. Intravenous amiodarone has been used as a bolus only or as a bolus followed by a continuous i.v. infusion until conversion or up to 24 It. The dose of i.v. bolus given ranged from 3 to 7 mg/kg body weight and that of infusion from 900 to 3000 mg/day. The efficacy reported is 34-69% with the bolus only regimens, and 55-95% with the bolus followed by infusion regimens. Only the higher dose (>1500 mg/day) amiodarone is superior to placebo in converting recent-onset atrial fibrillation to sinus rhythm. The highest 24-h conversion rates have been reported with the i.v. regimen of 125 mg/h until conversion or a maximum of 3 g and the oral regimen of 25-30 mg/kg body weight administered as a single loading-dose (>90% and >85%, respectively). Most of the conversions occur after 6-8 h of the initiation of therapy. Predictors of successful conversion are shorter duration of atrial fibrillation, smaller left atrial size, and higher amiodarone dose. Amiodarone is not superior to the other antiarrhythmic drugs conventionally used for the pharmacological cardioversion of recent-onset atrial fibrillation but is relatively safe in patients with structural heart disease and in those with depressed left ventricle function. Therefore, amiodarone could be used particularly in patients with structural heart disease and in those with left ventricular systolic dysfunction as the use of class IC drugs, propafenone and flecamide, for cardioversion of atrial fibrillation is contraindicated in such patients. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 27 条
[21]   PARENTERAL MAGNESIUM-SULFATE VERSUS AMIODARONE IN THE THERAPY OF ATRIAL TACHYARRHYTHMIAS - A PROSPECTIVE, RANDOMIZED STUDY [J].
MORAN, JL ;
GALLAGHER, J ;
PEAKE, SL ;
CUNNINGHAM, DN ;
SALAGARAS, M ;
LEPPARD, P .
CRITICAL CARE MEDICINE, 1995, 23 (11) :1816-1824
[22]  
NEGRINI M, 1990, Giornale Italiano di Cardiologia, V20, P207
[23]   INTRAVENOUS AMIODARONE VERSUS VERAPAMIL FOR ACUTE CONVERSION OF PAROXYSMAL ATRIAL-FIBRILLATION TO SINUS RHYTHM [J].
NOC, M ;
STAJER, D ;
HORVAT, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (09) :679-680
[24]   Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation [J].
Peuhkurinen, K ;
Niemelä, M ;
Ylitalo, A ;
Linnaluoto, M ;
Lilja, M ;
Juvonen, J .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (04) :462-465
[25]  
PILATI G, 1991, CURR THER RES CLIN E, V49, P140
[26]   EFFICACY OF INTRAVENOUS AMIODARONE IN THE MANAGEMENT OF PAROXYSMAL OR NEW ATRIAL-FIBRILLATION WITH FAST VENTRICULAR RESPONSE [J].
STRASBERG, B ;
ARDITTI, A ;
SCLAROVSKY, S ;
LEWIN, RF ;
BUIMOVICI, B ;
AGMON, J .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1985, 7 (01) :47-55
[27]   EFFICACY AND SAFETY OF SHORT INTRAVENOUS AMIODARONE IN SUPRAVENTRICULAR TACHYARRHYTHMIAS [J].
VIETTIRAMUS, G ;
VEGLIO, F ;
MARCHISIO, U ;
BURZIO, P ;
LATINI, R .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1992, 35 (01) :77-85